跳至主要内容
临床试验/CTRI/2020/05/025231
CTRI/2020/05/025231已完成未知

Analysis of clinical characteristics, toxicities and outcomes of hormone receptor positive, her 2 negative metastatic breast cancer patients treated with CDK4/6 inhibitors palbociclib from January 2016 till December 2018

Tata Memorial Centre0 个研究点目标入组 101 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
101

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • i.Patients with histopathologically confirmed ER/PR positive and HER- 2 negative metastatic breast cancer.
  • ii.Patients who have been started on palbociclib with atleast one record of treatment with palbociclib from the year January 2016 till December 2018 will be included in study. Data will be obtained from the electronic medical records from our hospital

排除标准

  • i.Patients having HER- 2 positive metastatic breast cancer.
  • ii.Patients receiving Palbacoclib or Ribocliclib under any industry sponsored trials
  • iii.Patientâ??s on palbociclib but not having details on EMR

研究者

相似试验